CINXE.COM

<!DOCTYPE html><html lang="en" class="h-100"><head><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title> UCSF Breast Cancer Clinical Trials for 2025 — San Francisco Bay Area</title><meta property="og:title" content="UCSF Breast Cancer Clinical Trials — San Francisco Bay Area"><meta name="description" content="Do you qualify for these Breast Cancer studies? We offer 43 options."><meta property="og:description" content="Do you qualify for these Breast Cancer studies? We offer 43 options."><meta property="og:url" content="https://clinicaltrials.ucsf.edu/breast-cancer"><link rel="canonical" href="https://clinicaltrials.ucsf.edu/breast-cancer"><meta name="author" content="UCSF"><meta name="generator" content="edu.ucsf.ctsi.rt.trialfinder"><meta name="referrer" content="origin-when-cross-origin"><meta name="google-site-verification" content="JXe923j97sTSgp-6yxsCdd25Muv0wMNfDR27ba3ER8M"><meta name="msvalidate.01" content="4E5209CC6688B86BBDD2FE074176C029"><link rel="shortcut icon" href="https://clinicaltrials.ucsf.edu/assets/local/ucsf/img/favicon.png"><link rel="alternate" type="application/atom+xml" title="UCSF Clinical Trials" href="https://clinicaltrials.ucsf.edu/meta/feed.atom"><meta property="og:type" content="website"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ucsf"><meta property="og:image" content="https://clinicaltrials.ucsf.edu/assets/local/ucsf/img/share-image.jpg"><link rel="stylesheet" href="https://clinicaltrials.ucsf.edu/assets/local/ucsf/ucsf_identity/banners.css"> <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.4.1/dist/css/bootstrap.min.css" integrity="sha256-L/W5Wfqfa0sdBNIKN9cG6QA5F2qx4qICmU2VgLruv9Y=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdn.jsdelivr.net/gh/coliff/bootstrap-rfs@4.3.1/bootstrap-rfs.css" media="screen and (max-width: 1200px)" integrity="sha256-DgOE2c1ekD0TaTyiCQuH2NdeiZ6VifYJdLdfDwq6C+U=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/animate.css@3.7.2/animate.min.css" integrity="sha256-PHcOkPmOshsMBC+vtJdVr5Mwb7r0LkSVJPlPrp/IMpU=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/font-awesome@4.7.0/css/font-awesome.min.css" integrity="sha256-eZrrJcwDc/3uDhsdt61sL2oOBY362qM3lon1gyExkL0=" crossorigin="anonymous"><link rel="stylesheet" href="https://clinicaltrials.ucsf.edu/assets/css/style.css"><link rel="stylesheet" href="https://clinicaltrials.ucsf.edu/assets/local/ucsf/css/style-local.css"> <script src="https://polyfill-fastly.io/v3/polyfill.min.js?features=default%2CObject.assign%2CObject.entries%2CPromise%2CURLSearchParams%2CURL" crossorigin="anonymous" defer></script> <script src="https://cdn.jsdelivr.net/jquery/2.2.4/jquery.min.js" integrity="sha256-BbhdlvQf/xTY9gja0Dq3HiwQF8LaCRTXxZKRutelT44=" crossorigin="anonymous" defer></script><script src="https://cdn.jsdelivr.net/npm/bootstrap@4.4.1/dist/js/bootstrap.bundle.min.js" integrity="sha256-OUFW7hFO0/r5aEGTQOz9F/aXQOt+TwqI1Z4fbVvww04=" crossorigin="anonymous" defer></script> <link rel="dns-prefetch" href="https://www.google.com/"> <script src="https://clinicaltrials.ucsf.edu/assets/js/app.js" defer></script><script>var google_analytics_live_mode=0;var google_analytics_id='UA-1142388-28';var google_analytics_hostname='clinicaltrials.ucsf.edu';if(google_analytics_id&&google_analytics_hostname&&window.location&&window.location.hostname&&window.location.hostname===google_analytics_hostname){google_analytics_live_mode=1}var google_analytics_js_url='https://www.google-analytics.com/analytics_debug.js';if(google_analytics_live_mode){google_analytics_js_url='https://www.google-analytics.com/analytics.js'}(function(c,h,e,b,f,a,d){c['GoogleAnalyticsObject']=f;c[f]=c[f]||function(){(c[f].q=c[f].q||[]).push(arguments)},c[f].l=1*new Date();a=h.createElement(e),d=h.getElementsByTagName(e)[0];a.async=1;a.src=b;d.parentNode.insertBefore(a,d)})(window,document,'script',google_analytics_js_url,'ga');if(!google_analytics_live_mode){}if(google_analytics_live_mode){ga('create',google_analytics_id,'auto')}else{ga('set','sendHitTask',null)}ga('require','outboundLinkTracker');ga('require','pageVisibilityTracker');ga('send','pageview');var s_opt={};s_opt['s_apid']='53G5XLK75T';s_opt['s_ixnm']='trials_ucsf';s_opt['s_ixky']='6e038166fd15da69c2ed075975c00816';s_opt['s_plac']=undefined;s_opt['s_mlti']=false;var _paq=window._paq=window._paq||[];_paq.push(['setTrackerUrl','https://clinicaltrials.ucsf.edu/action/t/l/']);_paq.push(['setSiteId','9']);_paq.push(['setCustomDimension',1,'condition\u002dpage']);_paq.push(['trackPageView']);_paq.push(['enableLinkTracking']);_paq.push(['enableHeartBeatTimer']);(function(){var a=document,g=a.createElement('script'),s=a.getElementsByTagName('script')[0];g.type='text/javascript';g.async=true;g.src='https://clinicaltrials.ucsf.edu/action/t/js/';s.parentNode.insertBefore(g,s)})();</script><script async src="https://cdn.jsdelivr.net/npm/autotrack@1.0.3/autotrack.js" integrity="sha256-MFv0PQKCj7HPlACiJTgQ+3rHnOSY1a510jcQGGwtemQ=" crossorigin="anonymous"></script><script type="application/ld+json"> { "@context": "https://schema.org/", "@type": "WebSite", "publisher": { "@type": "MedicalOrganization", "name": "UCSF", "address": "San Francisco Bay Area", "url": "https://www.ucsf.edu/", "logo": "https://s2.googleusercontent.com/s2/favicons?domain_url=https%3A%2F%2Fwww.ucsf.edu%2F", "sameAs": [ "https://twitter.com/@ucsf" ] } } </script><meta name="ahrefs-site-verification" content="5f73483e1fea16c76799e8797bf1b843c1c0cda17921ee5e1670f98bd81223f4"><link rel="dns-prefetch" href="https://researcherprofiles.org/"></head><body class="condition-page bg-light d-flex flex-column"> <a id="skip-to-main-content" class="sr-only sr-only-focusable" href="#content">Skip to main content</a> <header id="header" class="mb-4"><div id="ucsf-banner-nav"><div class="container-fluid"><div class="top-header-container" style="max-width: 100%"><div><ul class="menu"><li class="first"><a href="https://www.ucsf.edu">University of California San Francisco</a></li><li><a href="https://www.ucsfhealth.org/">UCSF Medical Center</a></li><li><a href="https://www.ucsf.edu/search">Search UCSF</a></li><li><a href="https://www.ucsf.edu/about">About UCSF</a></li></ul></div></div></div></div><nav class="navbar navbar-expand-md navbar-light d-print"> <a class="navbar-brand" href="https://clinicaltrials.ucsf.edu/"> <img src="https://clinicaltrials.ucsf.edu/assets/local/ucsf/img/site-name.png" alt="UCSF Clinical Trials"> </a> <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbar--menu--primary-content" aria-controls="navbar--menu--primary-content" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="collapse navbar-collapse justify-content-end" id="navbar--menu--primary-content"><ul class="navbar-nav"> <li class="nav-item" id="navbar--menu--home"> <a class="nav-link" href="https://clinicaltrials.ucsf.edu/">Search</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="https://clinicaltrials.ucsf.edu/browse/" id="navbar--menu--browse-dropdown-link" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Browse </a> <div class="dropdown-menu dropdown-menu-right" aria-labelledby="navbar--menu--browse-dropdown-link"> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/">All trials</a> <div class="dropdown-divider"></div><div class="dropdown-header">Trials for…</div> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/healthy">Healthy volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/pediatric" title="Pediatric clinical trials, for people under age 18">People under 18</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/geriatric" title="Geriatric clinical trials, for people over age 65">People over 65</a> <div class="dropdown-divider"></div><div class="dropdown-header">Trials seeking…</div> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/black" title="Trials that may be particularly relevant to Black volunteers"> Black volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/chinese" title="Trials that may be particularly relevant to Chinese volunteers"> Chinese volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/korean" title="Trials that may be particularly relevant to Korean volunteers"> Korean volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/latinx" title="Trials that may be particularly relevant to Latinx volunteers"> Latinx volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/lgbtqia" title="Trials that may be particularly relevant to LGBTQIA+ volunteers"> LGBTQIA+ volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/mena" title="Trials that may be particularly relevant to Middle Eastern or North African volunteers"> Middle Eastern or North African volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/native-american" title="Trials that may be particularly relevant to Native American volunteers"> Native American volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/native-hawaiian" title="Trials that may be particularly relevant to Native Hawaiian volunteers"> Native Hawaiian volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/south-asian" title="Trials that may be particularly relevant to South Asian volunteers"> South Asian volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/veteran" title="Trials that may be particularly relevant to Veteran volunteers"> Veteran volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/vietnamese" title="Trials that may be particularly relevant to Vietnamese volunteers"> Vietnamese volunteers</a> </div></li> <li class="nav-item" id="navbar--menu--equity" data-nosnippet> <a class="nav-link" href="https://clinicaltrials.ucsf.edu/about/equity">Equity <span class="d-none d-xl-inline">in Research</span></a></a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="https://clinicaltrials.ucsf.edu/about/" id="navbar--menu--about-dropdown-link" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> About <span class="d-none d-lg-inline">the site</span> </a> <div class="dropdown-menu dropdown-menu-right" aria-labelledby="navbar--menu--about-dropdown-link"> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/about/">About UCSF Clinical Trials</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/about/for-researchers">For Researchers</a> <div class="dropdown-divider"></div><div class="dropdown-header">Learn more in…</div> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/about/chinese" data-nosnippet>Chinese</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/about/spanish" data-nosnippet>Spanish</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/about/vietnamese" data-nosnippet>Vietnamese</a> </div></li></ul></div> </nav><nav class="breadcrumb-and-search-bar navbar navbar-expand navbar-light d-print d-flex justify-content-between"> <div><ol class="breadcrumb navbar-text my-0 pl-1" itemscope="itemscope" itemtype="https://schema.org/BreadcrumbList"><li itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"> <a href="https://clinicaltrials.ucsf.edu/" itemscope="itemscope" itemprop="item" itemtype="https://schema.org/Thing" id="navbar--breadcrumb--link-1"> Home <meta itemprop="name" content="UCSF Clinical Trials"> </a> <meta itemprop="position" content="1"></li><li class="active">Breast Cancer Studies</li></ol></div> <div><div class="d-none d-md-block navbar-text"><form method="GET" action="https://clinicaltrials.ucsf.edu/" class="form-inline my-1" role="search"> <label class="sr-only" for="header-search--input">Search</label> <input id="header-search--input" name="q" type="text" class="form-control form-control-sm" placeholder="Search UCSF clinical trials" title="Search clinical trials at UCSF"> <input class="sr-only form-control-sm btn btn-sm btn-secondary" type="submit" value="Search trials"> </form></div></div> </nav></header><main id="content" class="mx-1 mx-md-0"> <div class="container-md" itemscope itemtype="https://schema.org/WebPage"><div id="condition-header"><h1 class="mb-2" itemprop="headline"> <strong>Breast Cancer</strong> clinical trials at UCSF </h1><p class="h3 mb-5 text-muted" id="condition-header--clinical-trial-counts"><span data-nosnippet> 114 in progress, 43 open to eligible people </span></p><div class="row"><p id="condition-header--clinical-trial-portfolio-description" class="trials-list-header--explanatory-paragraph col col-md-9 col-lg-8" itemprop="description speakable"> Breast cancer is when cells in the breast grow out of control. UCSF is studying new ways to treat breast cancer, including testing a drug called Alisertib with hormone therapy for certain types of breast cancer. Another study is looking at the effects of a drug called Disitamab Vedotin alone or with other drugs in solid tumors. </p></div></div><div class="row"> <div class="col col-md-9 col-lg-8 "> <div class="trials-list--filter-container card bg-light text-center mb-3 d-none d-print-none" data-nosnippet><div class="card-body p-1"><span class="trials-list--filter-main-heading d-none d-md-inline"> Showing <span class="trials-list--number-of-trials-shown" aria-live="assertive"></span> trials for </span><div class="btn-group btn-group-sm btn-group-toggle ml-3" role="group" aria-label="Filter trials by sex/gender" data-toggle="buttons"> <label class="btn btn-light mr-1 active"> <input checked type="radio" name="trials-list--filter-sex" data-class-wanted=""> <i class="fa fa-male d-none d-lg-inline" aria-hidden="true"></i><i class="fa fa-female d-none d-lg-inline" aria-hidden="true"></i> All </label> <label class="btn btn-light mr-1"> <input type="radio" name="trials-list--filter-sex" data-class-wanted="trials-list--trial-open-to-sex-female"> <i class="fa fa-female d-none d-lg-inline" aria-hidden="true"></i> Female </label> <label class="btn btn-light mr-1"> <input type="radio" name="trials-list--filter-sex" data-class-wanted="trials-list--trial-open-to-sex-male"> <i class="fa fa-male d-none d-lg-inline" aria-hidden="true"></i> Male </label> </div><div class="btn-group btn-group-sm btn-group-toggle ml-3" role="group" aria-label="Filter trials by age range" data-toggle="buttons"> <label class="btn btn-light active"><input checked type="radio" name="trials-list--filter-age" data-class-wanted="">All ages</label> <label class="btn btn-light"><input type="radio" name="trials-list--filter-age" data-class-wanted="trials-list--trial-open-to-age-under-18">Under 18</label> <label class="btn btn-light"><input type="radio" name="trials-list--filter-age" data-class-wanted="trials-list--trial-open-to-age-18-and-over">Over 18</label> </div></div></div> <ul class="list-unstyled" id="trials-list"><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05086692" class="stretched-link">Beta-only IL-2 ImmunoTherapY Study</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Helen Diller Family Comprehensive Cancer Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04802759" class="stretched-link">Multiple Treatment Combinations in Participants With Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible females ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. Cohort 1 will focus on participants with inoperable, locally advanced or metastatic, estrogen receptor (ER)-positive, HER2-negative breast cancer who had disease progression during or following treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i; e.g., palbociclib, ribociclib, abemaciclib) in the first- or second-line setting. Cohort 2 will focus on inoperable, locally advanced or metastatic, ER-positive, HER2-positive breast cancer with previous progression to standard-of-care anti-HER2 therapies, of which one was a trastuzumab-and-taxane-based systemic therapy (including in the early setting if recurrence occurred within 6 months of finishing adjuvant therapy) and one was a HER2-targeting antibody-drug conjugate (ADC; e.g., ado-trastuzumab emtansine or trastuzumab-deruxtecan) or a HER2-targeting tyrosine kinase inhibitor (TKI; e.g., tucatinib, lapatinib, pyrotinib or neratinib). The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the patient population. During Stage 1, participants in each cohort will be randomly assigned to treatment arms. Participants in the control or experimental arms who experience unacceptable toxicity, disease progression as determined by the investigator according to RECIST v1.1, or loss of clinical benefit as determined by the investigator during Stage 1 will be given the option of receiving a different treatment combination during Stage 2, provided they meet eligibility criteria and a treatment arm is open for enrollment. No Stage 2 treatment is currently available.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF (UCSF)"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT06369285" class="stretched-link">Alisertib in Combination with Endocrine Therapy in Patients with HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is also planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in combination with endocrine and to identify the biomarker-defined subgroup(s) that may benefit most from combined alisertib and endocrine therapy.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF (UCSF) Helen Diller Family Comprehensive Cancer Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT06188559" class="stretched-link">BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The primary purpose of the Dose Optimization (Part 1) of this study is to assess the safety and tolerability of BB-1701 and to determine the recommended dose (RD) of BB-1701 for Dose Expansion (Part 2). The primary purpose of Dose Expansion (Part 2) is to assess the antitumor activity of BB-1701 at RD in the selected population(s) of breast cancer (BC).</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143-2208"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT06157892" class="stretched-link">Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®. This study will test how safe and how well DV, with or without tucatinib, is for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF | HDFCCC - Hematopoietic Malignancies"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT06099769" class="stretched-link">Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estrogen receptor-low breast cancer (ER-low BC), and whether these study treatments work as well as standard chemotherapy with carboplatin, paclitaxel, capecitabine, or eribulin.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF (Data collection only)"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05514054" class="stretched-link">Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF - John Muir Health Cancer Center Berkeley"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">Berkeley</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94702"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05107674" class="stretched-link">NX-1607 in Adults With Advanced Malignancies</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT06264921" class="stretched-link">NKT3447 for Adults with Advanced/Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of NKT3447 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and the preliminary antitumor activity of NKT3447 in adult subjects with cyclin E1 (CCNE1) amplified ovarian cancer at the RDEs selected in Dose Escalation and to determine the preliminary recommended phase 2 dose (RP2D).</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF (UCSF) - Helen Diller Family Comprehensive Cancer Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT06058377" class="stretched-link">Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Zuckerberg San Francisco General Hospital"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94110"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04379570" class="stretched-link">Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible females ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Cancer Center - Berkeley"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">Berkeley</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94702"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04893109" class="stretched-link">ATEMPT 2.0: Adjuvant T-DM1 Vs TH</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: - Trastuzumab-emtansine (T-DM1, Kadcyla) - Trastuzumab SC (Herceptin Hylecta) - Paclitaxel</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Helen Diller Family Comprehensive Cancer Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03971409" class="stretched-link">Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patient's immune system. This trial includes a two week induction or lead-in of medications that can stimulate the immune system. It is our hope that this induction will improve the response to immunotherapy with avelumab. One treatment, sacituzumab Govitecan, is a monoclonal antibody called sacituzumab linked to a chemotherapy drug called SN-38. Sacituzumab govitecan is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as Tumor-associated calcium signal transducer 2 (TROP2) receptors, and delivers SN-38 to kill them. Another treatment, liposomal doxorubicin, is a form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than doxorubicin, and may enhance factors associated with immune response. The third medication is called binimetinib, which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may help activate the immune system. It is not yet known whether giving avelumab in combination with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan will work better in treating patients with triple negative breast cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04862663" class="stretched-link">Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-99 </p><div class="trials-list--trial-summary"><p>A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Research Site"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT06075953" class="stretched-link">DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible females ages 18 years and up </p><div class="trials-list--trial-summary"><p>The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Participants will be asked to receive control hormonal therapy or an investigational hormonal therapy treatment. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation participants will have the option to continue on the treatment. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to provide blood sample to understand their immune status, provide saliva sample for genetic testing, provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04042701" class="stretched-link">DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Univ. of Cali. San Francisco Medical Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03990896" class="stretched-link">Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible females ages 18 years and up </p><div class="trials-list--trial-summary"><p>This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mission Bay/Benioff Children's Hospital"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05768139" class="stretched-link">First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate STX-478 as combination therapy with fulvestrant and a CDK4/6 Inhibitor (either Ribociclib or Palbociclib) in participants with HR+ breast cancer. Each study part will include a 28-day screening period, followed by treatment with STX-478 monotherapy or combination therapy.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT06055803" class="stretched-link">Heart Health After Cancer Treatment (HEART-ACT)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a pilot study testing multi-disciplinary health behavior intervention in breast cancer survivors who have been treated at Zuckerberg San Francisco General (ZSFG).</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Zuckerberg San Francisco General"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT01042379" class="stretched-link">I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF (UCSF)"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05056077" class="stretched-link">Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This clinical trial studies the effect of four different intervention components "tools" on body weight, nutrition, and physical activity in cancer survivors. Studies indicate that people with a history of cancer whose nutrition and physical activity habits are consistent with the American Cancer Society's Nutrition and Physical Activity Guidelines may have longer disease-free survival. The four different intervention components may help patients with a history of cancer adopt recommended health behaviors after they have completed treatment.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05020574" class="stretched-link">Microbiome and Association With Implant Infections</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible females ages 18 years and up </p><div class="trials-list--trial-summary"><p>The most common tissue expander-related infections are from Staphylococcus and Pseudomonas species. In addition, from breast tissue microbiome studies, Staphylococcus and Pseudomonas show variable abundance across samples. The investigator hypothesizes that participants undergoing mastectomy with high initial abundance of Staphylococcus and/or Pseudomonas are more likely to develop subsequent tissue expander-related infections from these respective organisms.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03589339" class="stretched-link">NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05563220" class="stretched-link">Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, abemaciclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Helen Diller Family Comprehensive Cancer Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05239143" class="stretched-link">P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05812807" class="stretched-link">Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Zuckerberg San Francisco General Hospital"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94110"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05508906" class="stretched-link">Combo w/ Ribociclib, Alpelisib, or Everolimus</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: OP-1250 in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation). Treatment Group 3: OP-1250 in combination with everolimus.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Health"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05232916" class="stretched-link">HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-100 </p><div class="trials-list--trial-summary"><p>This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of care therapy. Treatment consists of 6 intradermal injections, Primary Immunization Series (PIS), over the first 6 months of treatment and 5 booster intradermal injections spaced 6 months apart. A third open-label arm will explore GLSI-100 immunotherapy in non-HLA-A*02 positive and HER2/neu positive subjects.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF - Helen Diller Family Comprehensive Cancer Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-healthy "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04821141" class="stretched-link">Bazedoxifene Plus Conjugated Estrogens</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible females ages 45-64 </p><div class="trials-list--trial-summary"><p>Women at risk for development of breast cancer and experiencing vasomotor menopausal symptoms (hot flashes) will be randomized to bazedoxifene (BZA) plus conjugated estrogens (CE) for 6 months versus a wait list control. Two risk factors for development of breast cancer will be studied pre-study and after 6 months: fibroglandular volume (FGV) on mammogram as assessed by Volpara software and proliferation by Ki-67 immunocytochemistry in benign breast tissue acquired by random periareolar fine needle aspiration (RPFNA). Change in biomarkers will be compared between groups.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT06215469" class="stretched-link">Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 21 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this post-market, prospective study is to assess the ability of AMMA to prevent hair loss in women receiving chemotherapy (CT) for early-stage breast cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05323955" class="stretched-link">Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients with ADvanced Human Epidermal Growth Factor Receptor 2+ BrEast Cancer with the Addition of Tucatinib</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>Patients with advanced HER2+ breast cancer on maintenance trastuzumab/pertuzumab or T-DM1 with 1st or 2nd intracranial disease event (brain metastases) and stable extracranial disease will be enrolled. They will receive local therapy with stereotactic radiosurgery ± surgical resection if indicated followed by enrollment. Patients will continue standard of care trastuzumab/pertuzumab or T-DM1 with the addition of tucatinib. Hormone receptor positive patients requiring endocrine therapy should continue. Study treatment will continue until disease progression or intolerable side effects. Patients on trial with extracranial disease progression with stable intracranial disease should continue tucatinib into next line of therapy.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05226871" class="stretched-link">Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this clinical trial is to provide study medicine(s) and learn about their safety. This study is seeking participants who: - Have benefited from ongoing study treatment as determined by the study doctor in a Pfizer-sponsored palbociclib Parent Study - Must agree to follow the reproductive criteria - Are willing and able to comply with all scheduled visits, treatment plans, and other study procedures - Can give signed informed consent documents Participants in this study will continue to receive treatment as they were in the parent study. The time by which participants will take part in this study is retrospective (after completed parent study). We will examine the experiences of people receiving the study medicine(s). This will help us determine if the study medicine(s) are safe. During this time, the participants will be monitored for the safety of the study medicine(s).</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center at Mission Bay"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03562637" class="stretched-link">Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-821 in the adjuvant treatment of patients with high risk, early stage Globo-H Positive TNBC.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Helen Diller Family Comprehensive Cancer Centre"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04606446" class="stretched-link">PF-07248144 in Advanced or Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with either fulvestrant or letrozole + palbociclib or with PF-07220060 + fulvestrant</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center at Mission Bay"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05633654" class="stretched-link">Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT06084481" class="stretched-link">Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called cohorts. Each cohort receives ABBV-400 alone (monotherapy) followed by a safety follow-up period. Approximately 260 adult participants with hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancers (BTC), esophageal squamous cell carcinoma (ESCC), triple negative breast cancer (TNBC), hormone receptor+/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (hormone receptor-positive [HR+]/HER2-breast cancer [BC]), head and neck squamous-cell-carcinoma (HNSCC), Platinum Resistant High Grade Epithelial Ovarian Cancer (PROC)/primary peritoneal/fallopian tube cancer, or advanced solid tumors, will be enrolled in the study in approximately 54 sites worldwide. In the each cohorts, participants with the following advanced solid tumor indications: HCC, PDAC, BTC, ESCC, TNBC, HR+/HER2-BC, HNSCC, and PROC/primary peritoneal/fallopian tube cancer will receive intravenous (IV) ABBV-400 monotherapy for up to 2 years during and up to the treatment period with an additional safety follow-up period of up to 2 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF /Id# 257705"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04457596" class="stretched-link">T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Cancer Center - Berkeley"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">Berkeley</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94702"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05573555" class="stretched-link">TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer. This study is seeking participants who have breast cancer that: - is advanced, may have spread to other organs (metastatic) and cannot be fully treated by surgery or radiation therapy - is sensitive to hormonal therapy (it is called estrogen receptor positive); and - is no longer responding to previous treatments This study is divided into separate sub-studies. For Sub-Study B: All participants will receive ARV-471 and a medicine called ribociclib. ARV-471 and ribociclib will be given at the same time by mouth, at home, 1 time a day. The experiences of people receiving the study medicine will be examined. This will help determine if the study medicine is safe and effective. Participants will continue to take ARV-471 and ribociclib until their cancer is no longer responding, or side effects become too severe. They will have visits at the study clinic about every 4 weeks.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center at Mission Bay"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05564377" class="stretched-link">Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to all eligible people </p><div class="trials-list--trial-summary"><p>This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mission Bay"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-healthy "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT02620852" class="stretched-link">Women Informed to Screen Depending on Measures of Risk (Wisdom Study)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible females ages 30-74 </p><div class="trials-list--trial-summary"><p>Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended to have annual mammograms starting at age 40. Mammograms benefit women by detecting cancers early when they are easier to treat, but they are not perfect. Recent news stories have discussed some of the potential harms: large numbers of positive results that cause stressful recalls for additional mammograms and biopsies. With the current screening approach, half of the women who undergo annual screening for ten years will have at least one false positive biopsy. Potentially more important are cancer diagnoses for growths that might never come to clinical attention if left alone (called "overdiagnosis"). This can lead to unnecessary treatment. Even more concerning is evidence that up to 20% of breast cancers detected today may fall into the category of "overdiagnosis." This study compares annual screening with a risk-based breast cancer screening schedule, based upon each woman's personal risk of breast cancer. The investigators have designed the study to be inclusive of all, so that even women who might be nervous about being randomly assigned to receive a particular type of care (a procedure that is typical in clinical studies) will still be able to participate by choosing the type of care they receive. For participants in the risk-based screening arm, each woman will receive a personal risk assessment that includes her family and medical history, breast density measurement and tests for genes (mutations and variations) linked to the development of breast cancer. Women who have the highest personal risk of developing breast cancer will receive more frequent screening, while women with a lower personal risk would receive less frequent screening. No woman will be screened less than is recommended by the USPSTF breast cancer screening guidelines. If this study is successful, women will gain a realistic understanding of their personal risk of breast cancer as well as strategies to reduce their risk, and fewer women will suffer from the anxiety of false positive mammograms and unnecessary biopsies. The investigators believe this study has the potential to transform breast cancer screening in America.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05964504" class="stretched-link">Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94122"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05902507" class="stretched-link">Magnetic Resonance Imaging in Radiotherapy for Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a single-center, prospective pilot study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatment (RT) for breast cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03053193" class="stretched-link">MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Breast Care Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03737695" class="stretched-link">Clinical Information and Biospecimen Collection from Patients with Recurrent or Stage IV Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> currently not accepting new patients, but might later </p><div class="trials-list--trial-summary"><p>This trial collects clinical information and tissue and blood samples from patients with breast cancer that has come back or is stage IV. Collecting clinical information and biospecimen samples to create a registry may help doctors better understand the mechanism of tumor spread and determine why people respond differently to specific cancer treatments.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mission Bay"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05252416" class="stretched-link">(VELA) Study of BLU-222 in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Helen Diller Family Comprehensive Cancer Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03678883" class="stretched-link">9-ING-41 in Patients with Advanced Cancers</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Helen Diller Family Comprehensive Cancer Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04478279" class="stretched-link">Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04072952" class="stretched-link">ARV-471 Alone and in Combination with Palbociclib (IBRANCE®) in Patients with ER+/HER2- Locally Advanced or Metastatic Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and anti-tumor activity of ARV-471 alone and in combination with palbociclib (IBRANCE®) in patients with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer, who have received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Clinical Trial Site"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05451849" class="stretched-link">TC-510 In Patients With Advanced Mesothelin-Expressing Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex and second, a PD-1:CD28 switch receptor, which is expressed on the surface of the T cell, independently from the TCR. The PD-1:CD28 switch receptor comprises the PD-1 extracellular domain fused to the CD28 intracellular domain via a transmembrane domain. Thus, the switch is designed to produce a costimulatory signal upon engagement with PD-L1 on cancer cells.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT02498613" class="stretched-link">Cediranib in Combination With Olaparib in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also block the flow of oxygen to the tumor, and may help make the tumor more sensitive to olaparib.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mount Zion"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05104866" class="stretched-link">Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The study will evaluate the safety and efficacy of datopotamab deruxtecan (also known as Dato-DXd, DS-1062a), when compared with Investigator's choice of standard of care single-agent chemotherapy (eribulin, capecitabine, vinorelbine, or gemcitabine) in participants with inoperable or metastatic HR-positive, HER2- negative breast cancer who have been treated with one or two prior lines of systemic chemotherapy.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Research Site"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT02107703" class="stretched-link">Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The main purpose of this study is to compare progression-free survival for women with hormone receptor positive (HR+), human epidermal growth factor receptor (HER2) negative advanced breast cancer receiving either abemaciclib + fulvestrant or fulvestrant alone. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio. The study will last about 9 months for each participant. For the endocrine naïve cohort, all participants will received abemaciclib + fulvestrant.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT02779751" class="stretched-link">Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human epidermal growth factor receptor negative (HER2-) breast cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03289962" class="stretched-link">Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody).</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Comprehensive Cancer Ctr"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05374512" class="stretched-link">Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Research Site"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05307705" class="stretched-link">LOXO-783 in Patients With Breast Cancer/Other Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04188548" class="stretched-link">LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center at Mission Bay"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05852691" class="stretched-link">Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, tobemstomig, in combination with nab-paclitaxel, for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC).</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Comprehensive Cancer Ctr"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04539938" class="stretched-link">Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan (T-DXd). It will also look at what side effects happen when these drugs are given together. A side effect is anything a drug does besides treating cancer. Participants in this trial have HER2-positive (HER2+) breast cancer that has either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and T-DXd.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="University of California at San Francisco"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03975647" class="stretched-link">Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) or cannot be removed completely with surgery. Patients in this study will be randomly assigned to get either tucatinib or placebo (a pill with no medicine). This is a blinded study, so neither patients nor their doctors will know whether a patient gets tucatinib or placebo. All patients in the study will get T-DM1, a drug that is often used to treat this cancer. Each treatment cycle lasts 21 days. Patients will swallow tucatinib pills or placebo pills two times every day. Patients will get T-DM1 injections from the study site staff on the first day of every cycle.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="San Francisco General Hospital"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94110"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03845166" class="stretched-link">XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Exelixis Clinical Site #66"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT06105632" class="stretched-link">Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlikely to be cured or taken care of with treatment. Metastatic cancer is the one that has spread to other parts of the body. This study is seeking female and male participants who: - are 18 years of age or older; - are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; - have advanced or metastatic breast cancer after taking other treatments before this study; - have not taken or need to take medications that are not allowed by the study protocol; - do not have any medical or mental conditions that may increase the risk of study participation. Half of the participants will take PF-07220060 two times daily by mouth along with fulvestrant. Fulvestrant will be given as a shot into the muscle. The other half will take the study doctor's choice of treatment which can either be: - Fulvestrant alone taken as shot into the muscle. - Everolimus along with exemestane taken once daily by mouth. This study will compare the experiences of participants receiving the study medicine plus fulvestrant to those who are receiving the study doctor's choice of treatment. This will help decide if the study medicine is safe and effective. Participants will receive study treatment and/or will be in the study until: - imaging scans (such as an MRI and/or CT) show that their cancer is getting worse. - the study doctor thinks the participant is no longer benefitting from the study medicine. - has side effects that become too severe. A side effect is a reaction (expected or unexpected) to a medicine or treatment you take. - the participant chooses to stop taking part.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF - John Muir Health Cancer Center Berkeley"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">Berkeley</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94702"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT06206837" class="stretched-link">Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat. The study is seeking for participants who have breast cancer that: - is hard to treat (advanced) and may have spread to other organs (metastatic). - is sensitive to hormonal therapy (it is called estrogen receptor positive). - is no longer responding to treatments taken before starting this study. All the participants will receive vepdegestrant and PF-07220060. Both medicines will be taken by mouth. The medicines will be taken at home. The experience of people receiving the study medicines will be studied. This will help see if the study medicines are safe and effective. Participants will continue to take vepdegestrant and PF-07220060 until: - their cancer is no longer responding, or - side effects become too severe. They will have visits at the study clinic about every 4 weeks.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center at Mission Bay"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03701334" class="stretched-link">Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer (EBC)</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT06224673" class="stretched-link">ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not yet accepting patients </p><div class="trials-list--trial-summary"><p>This phase II trial tests how well ARX788 works in treating patients diagnosed with HER2-low, locally advanced unresectable or metastatic breast cancer. ARX788 is an antibody-drug conjugate (ADC) that is given by infusion (diluted and injected slowly into veins). Antibodies are proteins which are naturally produced by the body's immune system to help fight infections. ARX788 consists of antibodies that have been attached to a toxin that has the potential to kill cancer cells. ARX788 sticks to a protein called human epidermal growth factor receptor (HER2), which is found on some breast cancer cells. Giving ARX788 may be safe and effective in treating patients with HER2-low locally advanced unresectable metastatic breast cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04434040" class="stretched-link">Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: - Sacituzumab govitecan - Atezolizumab</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT02568267" class="stretched-link">Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Mount Zion Medical Ctr"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT02750826" class="stretched-link">Breast Cancer WEight Loss Study (BWEL Study)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were thinner when their cancer was diagnosed. This study aims to test whether overweight or obese women who take part in a weight loss program after being diagnosed with breast cancer have a lower rate of cancer recurrence as compared to women who do not take part in the weight loss program. This study will help to show whether weight loss programs should be a part of breast cancer treatment.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mount Zion"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04305496" class="stretched-link">Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Research Site"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04266249" class="stretched-link">CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Zuckerberg San Francisco General Hospital"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94110"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-healthy "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03233191" class="stretched-link">Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Zuckerberg San Francisco General Hospital"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94110"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03739931" class="stretched-link">mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Helen Diller Family Comprehensive Cancer Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT00433511" class="stretched-link">Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This randomized phase III trial studies doxorubicin hydrochloride, cyclophosphamide, and paclitaxel to see how well they work with or without bevacizumab in treating patients with cancer that has spread to the lymph nodes (lymph node-positive) or cancer that has not spread to the lymph nodes but is at high risk for returning (high-risk, lymph node-negative breast cancer). Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of breast cancer by blocking blood flow to the tumor. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery and help prevent the tumor from returning. It is not yet known whether doxorubicin hydrochloride, cyclophosphamide, and paclitaxel are more effective with or without bevacizumab.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Zuckerberg San Francisco General Hospital"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94110"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03529110" class="stretched-link">DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03155997" class="stretched-link">Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center at Mission Bay"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03941730" class="stretched-link">Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II trial studies how well estradiol works in treating patients with estrogen receptor beta (ER beta) positive, triple negative breast cancer that has spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). Hormone receptors like ER beta allow the body to respond appropriately to hormones. Triple negative means that the breast cancer does not express other hormone receptors called ER alpha, progesterone, and HER2. In some people with triple negative breast cancer, ER beta is overexpressed. Tumor cells that overexpress ER beta grow slower in the laboratory and this growth is slowed in the presence of estrogen. Estradiol is a form of estrogen. This study may help doctors determine whether tumor cells that overexpress ER beta shrink in the presence of estradiol.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mission Bay"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03781063" class="stretched-link">Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is an open label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of pre- and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an acquired ESR1 mutation and who have disease progression on an aromatase inhibitor (AI) in combination with a cyclin dependent kinase (CDK) 4/6 inhibitor. The primary objective is to evaluate the progression free survival (PFS) of 5 mg lasofoxifene relative to fulvestrant for the treatment of pre- and postmenopausal women with locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The secondary objectives are to evaluate: 1. Clinical benefit rate (CBR) and Objective Response Rate (ORR) 2. Duration of response 3. Time to response 4. Overall Survival (OS) 5. Pharmacokinetics of lasofoxifene 6. Quality of life (QoL): Quality of Life (QoL): vaginal assessment scale (VAS) and vulvar assessment scale (VuAS) questionnaires 7. Safety of lasofoxifene 8. Response to various ESR1 mutation (Y537S, Y537C, D538G, E380Q, S463P, V534E, P535H, L536H, L536P, L536R, L536Q, or Y537N).</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Cancer Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT01494662" class="stretched-link">HKI-272 for HER2-Positive Breast Cancer and Brain Metastases</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain. Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2). In this research study, the investigators are looking to see how well neratinib works to decrease the size of or stabilize breast cancer that has spread to the brain. The investigators are also looking at how previous treatments have affected your thinking (or cognition) and how much neratinib reaches the central nervous system.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT00310180" class="stretched-link">Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This randomized phase III trial studies the best individual therapy for women who have node-negative, estrogen-receptor positive breast cancer by using a special test (Oncotype DX), and whether hormone therapy alone or hormone therapy together with combination chemotherapy is better for women who have an Oncotype DX recurrence score of 11-25. Estrogen can cause the growth of breast cancer cells. Hormone therapy may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving hormone therapy together with more than one chemotherapy drug (combination chemotherapy) has been shown to reduce the chance of breast cancer recurrence, but the benefit of adding chemotherapy to hormone therapy for women with node-negative, estrogen-receptor positive breast cancer is small. New tests may provide information about which patients are more likely to benefit from chemotherapy.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Zuckerberg San Francisco General Hospital"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94110"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-open-to-healthy "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04542382" class="stretched-link">Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is an open-label, non-randomized, fixed-sequence study. Subjects will undergo a rosuvastatin phase and eltrombopag and rosuvastatin phase to identify biomarkers for Breast Cancer Resistance Protein (BCRP).</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Ctsi Crc"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT06633926" class="stretched-link">Integrative Approaches for Cancer Survivorship (IACS3)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not yet accepting patients </p><div class="trials-list--trial-summary"><p>This clinical trial is a two-arm pilot randomized controlled trial for non-metastatic breast cancer survivors to determine the feasibility, acceptability, and fidelity of two integrative health approaches and study design in a multi-site setting. Participants (n=104) will be randomized to either the Ayurveda Intervention (AVI) or Facing Forward Health Education Intervention (FFHEI). Integrative health combines biomedical and complementary approaches together in a coordinated way. AVI, a multi-modal intervention, includes nutritional education, lifestyle practices, yoga, and therapeutic touch, called marma, to help the body and mind feel balanced. FFHEI provides health education using self-directed online content and interactive videos based on the latest science in cancer survivorship. This study does not intend to conduct tests of efficacy and is focused on feasibility outcomes.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Zuckerberg San Francisco General"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT01570998" class="stretched-link">Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase IV trial studies the side effects of intraoperative radiation therapy and how well it works in treating patients with breast cancer undergoing breast-conserving surgery. Delivering radiation one time to the area where the tumor was removed while the patient is still in the operating room may kill any residual tumor cells and may be as effective as standard radiation therapy in patients with early stage breast cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT00382070" class="stretched-link">Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether letrozole is more effective than a placebo in treating patients with hormone receptor-positive breast cancer. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in treating postmenopausal women who have received hormone therapy for hormone receptor-positive breast cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="San Francisco General Hospital Medical Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94110"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03344965" class="stretched-link">Olaparib in Metastatic Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This research study is for patients with metastatic breast cancer. - Metastatic means that the cancer has spread beyond the breast. In addition, through genetic testing of the blood or tumor, an altered gene has been found that suggests the tumor may not be able to repair its genetic material (DNA) when it becomes damaged. - This aspect of the cancer may cause it to be more sensitive - that is, more effectively killed by certain types of drugs such as the study agent being evaluated in this trial, Olaparib. - Olaparib is a type of drug known as a PARP inhibitor. Some types of breast cancer and ovarian cancer share some basic features that make them sensitive to similar treatments. Information from those other research studies suggests that this drug may help to treat metastatic breast cancer. - This study will evaluate whether olaparib is effective in breast cancer patients whose tumor has a mutation in one of the other genes that function with BRCA1 and BRCA2 to repair damaged DNA .This mutation may have been inherited from a parent, or may have developed only in the tumor. - This study will also evaluate whether olaparib is effective in breast cancer patients whose tumor has a mutation in BRCA1 or BRCA2 that was acquired by the tumor, but not inherited.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT00770809" class="stretched-link">Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This randomized phase III trial studies paclitaxel and trastuzumab with or without lapatinib to see how well they work in treating patients with stage II or stage III breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving paclitaxel with trastuzumab and/or lapatinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known which regimen is more effective in treating patients with breast cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Zuckerberg San Francisco General Hospital"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94110"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT02513394" class="stretched-link">PALbociclib CoLlaborative Adjuvant Study</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC). The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer. Assessment of a variety of correlative analysis, including evaluation of the effect of palbociclib in genomically defined tumor subgroups, is planned.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Helen Diller Comprehensive Cancer Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT06648278" class="stretched-link">Patient Care Outreach, Navigation, Technology and Support 2.0</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a feasibility study employing virtual patient navigation for underserved individuals who speak English, Chinese or Spanish and were diagnosed with breast cancer to determine the extent of usability for a virtual patient navigation portal serving people in underserved communities. While not able to entirely replace in-person interactions, virtual patient navigation may be used to expand reach and availability of navigation services to a much greater segment of the population.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Zuckerberg San Francisco General Hospital"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94110"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT02947685" class="stretched-link">Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT00070564" class="stretched-link">S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating resected breast cancer. PURPOSE: This randomized phase III trial is comparing 2 different regimens of combination chemotherapy to see how well they work in treating patients who have undergone surgery for stage I, stage II, or stage III breast cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Helen Diller Family Comprehensive Cancer Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT01674140" class="stretched-link">S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet know whether hormone therapy is more effective when given with or without everolimus in treating breast cancer. PURPOSE: This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Zuckerberg San Francisco General Hospital"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94110"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT01872260" class="stretched-link">LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this trial is to inform the future clinical development of the two investigational agents in ER+ breast cancer, LEE011 (CDK4/6 inhibitor) and BYL719 (PI3K-alpha inhibitor). This is a multi-center, open-label Phase Ib study. The Phase Ib dose escalation will estimate the MTD and/or RP2D for three regimens: two double combinations, LEE011 with letrozole and BYL719 with letrozole, followed by triple combinations of LEE011 + BYL719 with letrozole (Arms 3 and 4). The Phase Ib dose escalation part will be followed by Phase Ib dose expansions to further characterize the safety, tolerability, PK and preliminary clinical anti-tumor activity of the combinations. Optional crossover for patients who have progressed while on dose escalation or dose expansion with doublet treatment on Arms 1 or 2 to be treated with the triplet combination (Arm 3) after the determination of the RP2D for Arm 3; is no longer permitted after protocol amendment 6. Approximately 270 adult women with ER+/HER2- locally advanced or metastatic breast cancer will be enrolled.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04191135" class="stretched-link">Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab (MK-3475) with chemotherapy plus pembrolizumab after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The primary hypotheses are: 1. Olaparib plus pembrolizumab is superior to chemotherapy plus pembrolizumab with respect to progression-free survival (PFS). 2. Olaparib plus pembrolizumab is superior to chemotherapy plus pembrolizumab with respect to overall survival (OS). As of Amendment 3, study enrollment was discontinued. Participants who were receiving benefit from the study intervention could continue treatment until criteria for discontinuation are met. Participants who are on study treatment or in follow-up phase will no longer have tumor response assessments by BICR.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0138)"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04895358" class="stretched-link">Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's choice of chemotherapy in the treatment of chemotherapy-candidate hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally recurrent inoperable or metastatic breast cancer. The primary hypotheses are that the combination of pembrolizumab and chemotherapy is superior to placebo and chemotherapy in regards to Progression-Free Survival (PFS) in participants with programmed cell death-ligand 1 (PD-L1) combined positive score (CPS) ≥1.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center at Mission Bay ( Site 0043)"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03422003" class="stretched-link">Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This study is a randomized trial of hypofractionation (short-course) radiation therapy versus conventional radiation therapy in women who have undergone mastectomy and immediate breast reconstruction. The investigators will assess cosmetic and reconstruction outcomes, lymphedema, cancer status, side effects, and oncologic outcomes.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05840211" class="stretched-link">Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to currently available standard treatments, such as paclitaxel, nab-paclitaxel or capecitabine. The primary objective is to compare the effect of SG relative to the treatment of physician's choice (TPC) on progression-free survival (PFS).</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF (UCSF) Helen Diller Family Comprehensive Cancer Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-healthy "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04711109" class="stretched-link">Denosumab on Preventing Breast Cancer in Women with a BRCA1 Germline Mutation</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. A germline mutation is an inherited gene change which, in the BRCA1 gene, is associated with an increased risk of breast and other cancers. Denosumab is a monoclonal antibody that is used to treat bone loss in order to reduce the risk of bone fractures in healthy people, and to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women carrying a BRCA1 germline mutation.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mount Zion"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT00066690" class="stretched-link">Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer. PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="San Francisco General Hospital"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94110"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT01853748" class="stretched-link">T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigational" means that the drug is still being studied and that research doctors are trying to find out more about it-such as the safest dose to use, the side effects it may cause, and if the drug is effective for treating different types of cancer. It also means that the FDA has not approved this drug for use patients undergoing adjuvant treatment for HER2+ breast cancer. Trastuzumab emtansine (T-DM1) is a drug that may stop cancer cells from growing. This drug has been used in other research studies and information from those other research studies suggests that this drug may help to prevent the recurrence of breast cancer in this research study. The use of T-DM1 in this research study is experimental, which means it is not approved by any regulatory authority for the adjuvant treatment of HER2-positive breast cancer. However, it FDA-approved for metastatic HER2-positive breast cancer. T-DM1 has caused cancer cells to die in laboratory studies. In preclinical studies, this drug has prevented or slowed the growth of breast cancer. The breast cancer treatments (paclitaxel and Trastuzumab) used in this study are considered part of standard-of-care regimens in early breast cancer. A standard treatment means that this is a treatment that would be accepted by the majority of the medical community as a suitable treatment for your type of breast cancer. In this research study, the investigators are looking to see if the study drug T-DM1 will have less side effects than traditional HER2-positive breast cancer treatment of trastuzumab and paclitaxel. The investigators are also hoping to learn about the long term benefits and disease-free survival of participants who take the study drug T-DM1 in comparison to those participants to take the combination of trastuzumab and paclitaxel.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03554044" class="stretched-link">T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase Ib trials studies the side effects and how well talimogene laherparepvec works when given together with chemotherapy or endocrine therapy in treating patients with breast cancer that does not express the human epidermal growth factor receptor 2 (HER2) protein and has spread to other places in the body (metastatic), cannot be removed by surgery (unresectable), or has come back (recurrent). Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may attack specific tumor cells and stop them from growing or kill them. Chemotherapy drugs, such as nab-paclitaxel, gemcitabine, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Estrogen can cause the growth of breast cancer cells. Drugs used as endocrine therapy, such as letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, may lessen the amount of estrogen made by the body or may may stop the growth of tumor cells by blocking estrogen from connecting to the cancer cells. Giving talimogene laherparepvec with chemotherapy or endocrine therapy may work better in treating patients with HER2-negative breast cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT05548127" class="stretched-link">TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer. This study is seeking participants who have breast cancer that: - is advanced, may have spread to other organs (metastatic) and cannot be fully treated by surgery or radiation therapy - is sensitive to hormonal therapy (it is called estrogen receptor positive); and - is no longer responding to previous treatments This study is divided into separate sub-studies. For Sub-Study A: All participants will receive ARV-471 and a medicine called abemaciclib. ARV-471 will be given by mouth, at home, 1 time a day. Abemaciclib will be given by mouth, at home, 2 times a day. We will examine the experiences of people receiving the study medicines. This will help us determine if the study medicines are safe and effective. Participants will continue to take ARV-471 and abemaciclib until their cancer is no longer responding, or side effects become too severe. They will have visits at the study clinic about every 4 weeks.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center at Mission Bay"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT00601900" class="stretched-link">Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This randomized phase III trial studies tamoxifen citrate or letrozole together with bevacizumab to see how well it works compared with tamoxifen citrate or letrozole alone in treating women with stage IIIB or stage IV breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate or letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells. Immunotherapy with monoclonal antibodies, such as bevacizumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving hormone therapy is more effective with or without bevacizumab in treating advanced breast cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="Zuckerberg San Francisco General Hospital"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94110"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT02849496" class="stretched-link">Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This randomized phase II trial studies how well olaparib with or without atezolizumab work in treating patients with non-HER2-positive breast cancer that has spread to nearby tissue or lymph nodes (locally advanced), that cannot be removed by surgery (unresectable), or that has spread from where it first started (primary site) to other places in the body (metastatic). Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. It is not known whether giving olaparib with or without atezolizumab will work better in patients with non-HER2-positive breast cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mount Zion"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT00548236" class="stretched-link">Active After Cancer Trial (AACT)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This study is being done to determine whether a telephone-based counseling intervention can help survivors of breast and colorectal cancer increase their weekly physical activity. Observational evidence suggests that physical activity after breast and colorectal cancer diagnosis decreases recurrence rates. Unfortunately, many people become less active during cancer therapy, and a substantial proportion never return to pre-diagnosis levels of physical activity. This study looks to see if people who have recently finished chemotherapy for breast, colon or rectal cancer can be motivated to increase their exercise by talking to an exercise specialist over the phone. The study also looks at changes in mood, fatigue, fitness, fat distribution and weight.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03414658" class="stretched-link">AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This research study is studying a combination of drugs as a possible treatment for breast cancer. The drugs involved in this study are: - Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine) - Group B: Trastuzumab + Vinorelbine + Avelumab - Group C: Trastuzumab + Vinorelbine + Avelumab + Utomilumab (PF-05082566)</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03734029" class="stretched-link">Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before. Participants' cancer: - Cannot be removed by an operation - Has spread to other parts of the body</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="University of California at San Francisco (PARENT)"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT00066703" class="stretched-link">Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen. It is not yet known whether giving triptorelin together with exemestane is more effective than triptorelin and tamoxifen in treating hormone-responsive breast cancer. PURPOSE: This randomized phase III trial is studying triptorelin and exemestane to see how well they work compared to triptorelin and tamoxifen in treating premenopausal women with hormone-responsive breast cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Helen Diller Family Comprehensive Cancer Center"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03501979" class="stretched-link">Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>A phase 2 non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab with capecitabine for the treatment of leptomeningeal metastases in HER2-neu positive breast cancer.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF-Mission Bay"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04316117" class="stretched-link">FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II trial studies how well FDG-PET/CT works in assessing the response of patients with breast cancer that has spread to the bones or mostly to the bones (bone-dominant metastatic breast cancer). Diagnostic procedures, such as FDG-PET/CT, may work better in measuring breast cancer activity before and after treatment compared to other standard imaging tests.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Medical Center-Mission Bay"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT04395508" class="stretched-link">Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not accepting new patients </p><div class="trials-list--trial-summary"><p>This single arm, multicenter study provides the pertuzumab and trastuzumab fixed-dose combination formulation for subcutaneous injection (PH FDC SC) administered at home by a home health nursing provider for patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer who have completed concurrent chemotherapy with pertuzumab (Perjeta) and trastuzumab (Herceptin) by intravenous administration (P+H IV) and are currently receiving or will be receiving maintenance therapy with P+H IV, PH FDC SC, or trastuzumab SC in the clinic. The main objective is to enable continuity of care during the COVID-19 pandemic. This study will enroll approximately 200 patients in the United States. Participants with early or metastatic HER2+ breast cancer will be enrolled in this study. Participants with metastatic HER2+ breast cancer will receive treatment every 3 weeks and continue treatment unless early cessation is necessary due to disease recurrence, disease progression, unacceptable toxicity, participant withdrawal of consent, or per physician's recommendation. Participants with early HER2+ breast cancer will receive PH FDC SC to complete 1 year (up to 18 cycles) of dual blockade, including the P+H IV, PH FDC SC, or trastuzumab SC they received prior to enrolling in this study, unless early cessation is necessary due to disease recurrence, disease progression, unacceptable toxicity, participant withdrawal of consent, or per physician's recommendation. A remote cardiac surveillance substudy will be optional for patients enrolled at select sites. The Sponsor may decide to terminate the study when the COVID-19 pandemic is no longer a risk for this patient population.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF Helen Diller Family CCC"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94158"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT00941759" class="stretched-link">Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this study is to study patients presenting with stage IV breast cancer. Stage IV means that the breast cancer has spread to another part of the body outside the breast. This study is important because in different parts of the country some patients are being offered surgical treatment for the breast tumor and some are not. The doctors do not know if surgery for the breast tumor is helpful in patients with stage IV breast cancer. The doctors will collect information about the patient and their treatment to learn more about how patients and doctors make treatment decisions. The doctor will also collect blood samples and tissue samples for laboratory studies to learn more about tumors that have spread to other parts of the body.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT03906331" class="stretched-link">Treatment of Cancers With Rearranged During Transfection (RET) Activation</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not accepting new patients </p><div class="trials-list--trial-summary"><p>Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT01101425" class="stretched-link">Male Breast Cancer: Understanding the Biology for Improved Patient Care</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>Rationale: Gathering medical information and tumor samples from patients with male breast cancer may help doctors learn more about the disease. Purpose retrospective part: to perform a large international retrospective analysis of clinical and biological data of male BC patients treated in the participating centers from 1990 to 2010. Purpose prospective part: to create a registry of men with breast cancer for a period of 30 months (starting early 2014).</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF UCSF Medical Center-Mount Zion"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT06234488" class="stretched-link">Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>There is no granular retrospective data on breast cancer in transgender and gender-diverse (TGD) persons from a contemporary and diverse American cohort. The purpose of this investigation is to aggregate data from multiple institutions to describe the risk, diagnosis, management, and outcomes of TGD persons with breast cancer in effort to identify opportunities for future intervention studies to eliminate breast cancer disparities for this population.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF (UCSF)"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94115"><meta itemprop="addressCountry" content="United States"> </strong> and other locations </span></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-open-to-healthy "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucsf.edu/trial/NCT06774027" class="stretched-link">Registry of ADC as First- and Second-line Treatment for Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not yet accepting patients </p><div class="trials-list--trial-summary"><p>Antibody-drug conjugates (ADCs) have demonstrated substantial improvement in progression free survival (PFS) and overall survival (OS) in phase III clinical trials in patients with metastatic triple negative breast cancer (mTNBC) and hormone receptor positive/HER2 negative (HR+/HER2-) metastatic breast cancer (MBC), offering an effective new treatment strategy. Several outstanding questions drive the decision to use ADC drugs clinically. This is a prospective, multi-site observational study of patients with metastatic breast cancer (mBC) who are being treated with FDA-approved antibody drug conjugates (ADCs) as part of routine care and aims to collect real-world data to evaluate the impact of ADC treatment as part of routine care.</p></div><p itemprop="location" itemscope itemtype="https://schema.org/Place" class="text-right text-muted small"><meta itemprop="name" content="UCSF"> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> <span itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"> <strong> <span itemprop="addressLocality">San Francisco</span>, <span itemprop="addressRegion">California</span><meta itemprop="postalCode" content="94143"><meta itemprop="addressCountry" content="United States"> </strong> </span></p></div></div></li></ul><div><p class="text-muted small comma-list"> Our lead scientists for Breast Cancer research studies include <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/pamela.munster" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Pamela Munster</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/lisa.singer" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Lisa Singer, MD, PhD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/niharika.dixit" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Niharika Dixit</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/anand.dhruva" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Anand Dhruva, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/adil.daud" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Adil Daud</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/collin.blakely" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Collin Blakely</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/laura.huppert" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Laura Huppert, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/nicholas.butowski" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Nicholas Butowski</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/rita.mukhtar" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Rita Mukhtar, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/michelle.melisko" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Michelle Melisko</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/scarlett.gomez" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Scarlett L Gomez, PhD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/laura.esserman" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Laura Esserman, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/rahul.aggarwal" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Rahul Aggarwal</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/michael.alvarado" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Michael Alvarado</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/arun.rangaswami" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Arun A. Rangaswami</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/catherine.park" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Catherine Park</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/david.oh" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">David Oh</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/hope.rugo" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Hope Rugo</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/alexis.beatty" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Alexis Beatty, MD, MAS</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/merisa.piper" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Merisa Piper</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/erin.vanblarigan" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Erin Van Blarigan, ScD</span></a></span>. </p><p class="text-muted small">Last updated: <time itemprop="dateModified" datetime="2025-02-11">February 11, 2025</time></p></div></div> <div class="col-md-3 col-lg-3 offset-lg-1"><aside class="d-print-none"><h3 class="h5 mt-5" role="complementary">Related Links</h3><ul><li><a href="https://cancer.ucsf.edu/">UCSF Helen Diller Family Comprehensive Cancer Center</a></li><li><a href="https://www.breastcancertrials.org/metastatic-trial-search.html">Detailed Search for Metastatic Breast Cancer Trials</a></li><li><a href="https://www.breastcancertrials.org/">Breast cancer trials outside UCSF</a></li><li><a href="https://metastatictrialtalk.org/">Selected News about Metastatic Breast Cancer Research</a></li><li><a href="https://www.ucsfhealth.org/find-a-doctor/" rel="nofollow">UCSF Health doctors</a></li></ul></aside></div> </div> </div> </main><footer class="mt-auto" role="contentinfo" data-nosnippet><div id="ucsf--footer--body"><div class="container" data-nosnippet><div class="row mb-1 d-print-none"><div class="col-12 text-center text-md-left"> We use cookies to operate our website, analyze performance, and improve your experience on our site. <a href="https://www.ucsf.edu/website-privacy-policy" target="_blank">Learn more.</a> </div></div><div class="row"><div class="col-md-6 text-center text-md-left"><p class="my-0"> © The Regents of the University of California </p></div><div class="col-md-6 text-center text-md-right pt-3 pt-md-0"> <a href="https://websites.ucsf.edu/digital-accessibility" target="_blank">Accessibility</a> <a href="https://www.ucsf.edu/website-privacy-policy" target="_blank">Privacy Policy</a> <a href="https://websites.ucsf.edu/website-terms-use" target="_blank">Terms of Use</a> </div></div></div></div></footer><script>(function(){var b=document.createElement('script');b.type='text/javascript';b.async=true;b.src='//siteimproveanalytics.com/js/siteanalyze_8343.js';var a=document.getElementsByTagName('script')[0];a.parentNode.insertBefore(b,a)})();</script></body></html>